Medical Oncology

, 32:281 | Cite as

The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women

  • Samira Zoa Assoumou
  • Anicet Luc M. Boumba
  • Angelique Ndjoyi-Mbiguino
  • Abdelkrim Khattabi
  • Moulay Mustapha Ennaji
Original Paper


Cervical cancer is the leading cause of cancer-related death in Africa and the first most common cancer in Gabonese women due to infection of high-risk human papillomavirus (HPV). However, other cofactors such as genetic factors also come into play. A common polymorphism of the p53 codon 72 in exon 4 with two alleles encoding arginine or proline is known at this locus. The homozygous arginine form of this polymorphism has been associated with the development of cervical cancer as an increased genetic risk factor. However, the results are still controversial. This study aims to investigate whether the genotype distribution of p53 codon 72 may be a risk factor for cervical cancer among Gabonese women. Samples from 102 Gabonese women, 31 diagnosed with cervical cancer and 71 healthy controls, were used. HPV detection was done by nested PCR with MY09/11 and GP5+/6+ primers followed by sequencing for HPV genotyping. p53 codon 72 polymorphism determination was performed by allele-specific PCR assay. Viral DNA was detected in 87.1 % of cases and in 54.93 % of control. HPV 16 was the most predominant in cancer and controls cases. The distribution of Arg/Arg, Arg/Pro and Pro/Pro genotypes was 35.5, 51.6 and 12.9 % in the cervical cancer group and 22.5, 62 and 15.5 % in the control group. No significant association was found between polymorphism of p53 itself as well as in combination with HPV16/18 infection and risk of development of cervical cancer among Gabonese women. Thus, the polymorphism of p53 codon 72 in exon 4 does not seem to play a role in the development of cervical cancer among Gabonese women.


p53 codon 72 Polymorphism Cervical cancer Human papillomavirus Gabonese women 



The authors would like to express gratitude to Dr Mabicka Mabicka Barthélemy, Head of “Département d’Anatomie et de Cytologie Pathologiques de l’Université des Sciences de la Santé de Libreville,” Sophia Abassi and all technical staff of “Département d’Anatomie et de Cytologie Pathologiques de l’Université des Sciences de la Santé de Libreville.” We would also like to thank Pr. Ernerst Belembaogo, Head of “Institut de cancérologie d’Agondjé” and his staff for their precious technical assistance. This project was financially supported by the Moroccan Minister of Higher Education. We have also received technical assistance from UATRS-CNRST, Morocco for genotyping.

Conflict of interest



  1. 1.
    Achour M, Kochbati L, Zeghal D, Kahla S, Maalej M, Zouari F, et al. Serological study in Tunisian cervical cancer patients. Pathol Biol. 2009;57(5):415–9. doi: 10.1016/j.patbio.2008.05.004.PubMedCrossRefGoogle Scholar
  2. 2.
    Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer J Int Du Cancer. 2011;128(4):927–35. doi: 10.1002/ijc.25396.CrossRefGoogle Scholar
  3. 3.
    Finzer P, Aguilar-Lemarroy A, Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 2002;188(1–2):15–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992;12:197–217.PubMedGoogle Scholar
  5. 5.
    Gudleviciene Z, Didziapetriene J, Ramael M, Uleckiene S, Valuckas KP. Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol Oncol. 2006;102(3):530–3. doi: 10.1016/j.ygyno.2006.01.019.PubMedCrossRefGoogle Scholar
  6. 6.
    Jiang P, Liu J, Zeng X, Li W, Tang J. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. Cancer Genet Cytogenet. 2010;197(2):174–8. doi: 10.1016/j.cancergencyto.2009.11.011.PubMedCrossRefGoogle Scholar
  7. 7.
    Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):229–34. doi: 10.1038/30400.PubMedCrossRefGoogle Scholar
  8. 8.
    Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. JMD. 2011;13(4):377–81. doi: 10.1016/j.jmoldx.2011.03.007.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC clin Pathol. 2009;9:3. doi: 10.1186/1472-6890-9-3.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. doi: 10.1086/657321.PubMedCrossRefGoogle Scholar
  11. 11.
    Allan B, Marais DJ, Hoffman M, Shapiro S, Williamson AL. Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol. 2008;46(2):740–2. doi: 10.1128/JCM.01981-07.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Khair MM, Mzibri ME, Mhand RA, Benider A, Benchekroun N, Fahime EM, et al. Molecular detection and genotyping of human papillomavirus in cervical carcinoma biopsies in an area of high incidence of cancer from Moroccan women. J Med Virol. 2009;81(4):678–84. doi: 10.1002/jmv.21279.PubMedCrossRefGoogle Scholar
  14. 14.
    Abba MC, Villaverde LM, Gomez MA, Dulout FN, Laguens MR, Golijow CD. The p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol. 2003;109(1):63–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Tachezy R, Mikyskova I, Salakova M, Van Ranst M. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet. 1999;105(6):564–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Baek WK, Cho JW, Suh SI, Suh MH, Shin DH, Cho CH, et al. p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. J Korean Med Sci. 2000;15(1):65–7.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Settheetham-Ishida W, Kanjanavirojkul N, Kularbkaew C, Ishida T. Human papillomavirus genotypes and the p53 codon 72 polymorphism in cervical cancer of Northeastern Thailand. Microbiol Immunol. 2005;49(5):417–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Bhattacharya P, Duttagupta C, Sengupta S. Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian women. Cancer Lett. 2002;188(1–2):207–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998;352(9131):871–2. doi: 10.1016/S0140-6736(98)07357-7.PubMedCrossRefGoogle Scholar
  20. 20.
    Mingrong X, Yuedong H, Xiaoyun Y, Minmin H, Zeyi C. The preliminary study on the relationship between HPV-associated cervical cancer and p53 codon 72 polymorphism in Sichuan province. Chin Ger J Clin Oncol. 2003;2(3):160–2.CrossRefGoogle Scholar
  21. 21.
    Mitra S, Misra C, Singh RK, Panda CK, Roychoudhury S. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol. 2005;58(1):26–31. doi: 10.1136/jcp.2004.019315.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev. 2000;9(2):113–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Tenti P, Vesentini N, Rondo Spaudo M, Zappatore R, Migliora P, Carnevali L, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer epidemiol biomarkers prev. 2009;9(4):435–8.Google Scholar
  24. 24.
    Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 1998;58(20):4585–6.PubMedGoogle Scholar
  25. 25.
    Kim JW, Roh JW, Park NH, Song YS, Kang SB, Lee HP. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol. 2001;184(2):55–8. doi: 10.1067/mob.2001.108329.PubMedCrossRefGoogle Scholar
  26. 26.
    El khair MM, Ennaji MM, El kebbaj R, Mhand RA, Attaleb M, El Mzibri M. p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women. Med Oncol. 2010; 27(3):861–6. doi: 10.1007/s12032-009-9297-6
  27. 27.
    Pegoraro R, Moodley J, Naiker S, Lanning P, Rom L. The p53 codon 72 polymorphism in black South African women and the risk of cervical cancer. BJOG. 2000;107(9):1164–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. MCBRC. 2000;3(2):111–4. doi: 10.1006/mcbr.2000.0196.PubMedGoogle Scholar
  29. 29.
    Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, et al. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol. 2002;86(2):157–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Eltahir HA, Adam AA, Yahia ZA, Ali NF, Mursi DM, Higazi AM, et al. p53 Codon 72 arginine/proline polymorphism and cancer in Sudan. Mol Biol Rep. 2012;39(12):10833–6. doi: 10.1007/s11033-012-1978-0.PubMedCrossRefGoogle Scholar
  31. 31.
    Eltahir HA, Elhassan AM, Ibrahim ME. Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mol Med Rep. 2012;6(3):473–6. doi: 10.3892/mmr.2012.942.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Malisic E, Jankovic R, Brotto K, Radulovic S. TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. Arch Gynecol Obstet. 2013;288(3):621–5. doi: 10.1007/s00404-013-2783-2.PubMedCrossRefGoogle Scholar
  33. 33.
    BrennaI SMF dSI, Zeferino LC, Pereira J, Martinez EZ, Syrjänen KJ Prevalence of codon 72 P53 polymorphism in Brazilian women with cervix cancer. Genet Mol Biol. 2004; 27(4). doi:  10.1590/S1415-47572004000400005
  34. 34.
    Pegoraro RJ, Rom L, Lanning PA, Moodley M, Naiker S, Moodley J. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer. 2002;12(4):383–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Samira Zoa Assoumou
    • 1
    • 2
  • Anicet Luc M. Boumba
    • 1
    • 2
  • Angelique Ndjoyi-Mbiguino
    • 3
  • Abdelkrim Khattabi
    • 2
  • Moulay Mustapha Ennaji
    • 1
  1. 1.Laboratoire de Virologie, Microbiologie et Qualité/Ecotoxicologie and Biodiversité, Faculté des Sciences et Techniques de MohammediaUniversité Hassan II Mohammedia CasablancaMohammediaMaroc
  2. 2.Laboratoire d’Agroalimentaire et Santé, Département de Biologie Appliquée, Faculté des Sciences et Techniques de SettatUniversité Hassan 1er SettatSettatMaroc
  3. 3.Laboratoire de Référence IST/Sida, Laboratoire de Référence Rougeole, Rubéole et Fièvre jaune, Département de Bactériologie et Virologie, Faculté de Médecine et des Sciences de la SantéUniversité des Sciences de la SantéLibrevilleGabon

Personalised recommendations